Reading the tape
NASDAQ: ATRC
AtriCure, Inc.
Healthcare · Medical - Instruments & Supplies
Market Cap
$1.46B
52w High
$43.18
52w Low
$26.62
P/E
-120.57
Volume
1.30M
Outstanding Shares
50.63M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -1%Revenue (TTM): 14.88%FCF (TTM): 498.55%P/S: 3rd pct
What changed
The stock fell 1% over the last year. Revenue grew 14.88% over the trailing twelve months. Operating margin moved from -8.6% to -1.58%. Free cash flow grew 498.55% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -1.58%. A decisive move in revenue — currently up 14.88% — would be the clearest signal to resolve the ambiguity.
Company profile
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.
CEOMichael H. Carrel
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees1,300
IPO dateAug 5, 2005
Valuation
Forward P/E—
EV/EBITDA111.39
Enterprise value$1.81B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth13.05%
Gross margin74.84%▼0.37%vs FY2024
Operating margin-1.58%▲92.50%vs FY2024
ROE-2.33%▲76.00%vs FY2024
Analyst consensus
RatingBuy
Target price$50.67▲76.06%
18
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 5, 2026
Q2 FY26 · EPS est -$0.07 · Revenue est $139.75M
View
Congressional Activity
Congress Trades in ATRC
STOCK Act disclosures from senators and representatives.
Gilbert Cisneros
CAhouseDemocratPurchase2026-03-03$1,001 - $15,000+36d to disclose